MX2021008213A - Derivados de (2,5-dioxopirrolidina-1-il)(fenil)-acetamida y su uso en el tratamiento de enfermedades neurologicas. - Google Patents

Derivados de (2,5-dioxopirrolidina-1-il)(fenil)-acetamida y su uso en el tratamiento de enfermedades neurologicas.

Info

Publication number
MX2021008213A
MX2021008213A MX2021008213A MX2021008213A MX2021008213A MX 2021008213 A MX2021008213 A MX 2021008213A MX 2021008213 A MX2021008213 A MX 2021008213A MX 2021008213 A MX2021008213 A MX 2021008213A MX 2021008213 A MX2021008213 A MX 2021008213A
Authority
MX
Mexico
Prior art keywords
treatment
dioxopyrrolidin
phenyl
neurological diseases
acetamide derivatives
Prior art date
Application number
MX2021008213A
Other languages
English (en)
Inventor
Krzysztof Kaminski
Michal Abram
Anna Rapacz
Szczepan Mogilski
Gniewomir Latacz
Bartlomiej Szulczyk
Original Assignee
Univ Jagiellonski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Jagiellonski filed Critical Univ Jagiellonski
Publication of MX2021008213A publication Critical patent/MX2021008213A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

El primer objeto de la invención es el compuesto de la fórmula general (I) o sus sales farmacéuticamente aceptables. Un segundo objeto de la invención es el uso de compuestos descritos por la fórmula general (I) como ingrediente activo en composiciones farmacéuticas para el tratamiento de ataques epilépticos o dolor neuropático o migraña.
MX2021008213A 2019-01-07 2020-01-07 Derivados de (2,5-dioxopirrolidina-1-il)(fenil)-acetamida y su uso en el tratamiento de enfermedades neurologicas. MX2021008213A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PL428485A PL244071B1 (pl) 2019-01-07 2019-01-07 Pochodne (2,5-dioksopirolidyn-1-ylo)(fenylo)-acetamidu i ich zastosowanie do leczenia chorób o podłożu neurologicznym
PCT/PL2020/050001 WO2020145831A1 (en) 2019-01-07 2020-01-07 (2,5-dioxopyrrolidin-l-yl)(phenyl)-acetamide derivatives and their use in the treatment of neurological diseases

Publications (1)

Publication Number Publication Date
MX2021008213A true MX2021008213A (es) 2021-08-11

Family

ID=69743891

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021008213A MX2021008213A (es) 2019-01-07 2020-01-07 Derivados de (2,5-dioxopirrolidina-1-il)(fenil)-acetamida y su uso en el tratamiento de enfermedades neurologicas.

Country Status (10)

Country Link
US (1) US20220073461A1 (es)
EP (1) EP3908580A1 (es)
JP (1) JP2022522949A (es)
CN (1) CN113272292B (es)
AU (1) AU2020207162A1 (es)
BR (1) BR112021013406A2 (es)
CA (1) CA3125321A1 (es)
MX (1) MX2021008213A (es)
PL (1) PL244071B1 (es)
WO (1) WO2020145831A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL244897B1 (pl) * 2021-11-24 2024-03-25 Univ Jagiellonski Deuterowane funkcjonalizowane pochodne α-alaniny, zwłaszcza do leczenia chorób neurologicznych
CN114920790B (zh) * 2022-04-28 2024-06-14 康龙化成(宁波)科技发展有限公司 一种寡聚核酸-二酰亚胺化合物的合成方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1244456B1 (en) * 1999-12-01 2007-05-09 Ucb, S.A. A pyrrolidineacetamide derivative for treatment of chronic or neuropathic pain
DE60138733D1 (de) * 2000-12-28 2009-06-25 Hamilton Pharmaceuticals Inc Arzneimittel zur behandlung und vermeidung neurogener schmerzen
EP1503761A1 (en) * 2002-05-10 2005-02-09 Neurocrine Biosciences, Inc. Substituted piperazines as melanocortin receptor ligands
CA2866302A1 (en) * 2012-03-19 2013-09-26 Abide Therapeutics, Inc. Carbamate compounds and of making and using same

Also Published As

Publication number Publication date
BR112021013406A2 (pt) 2021-09-14
PL244071B1 (pl) 2023-11-27
EP3908580A1 (en) 2021-11-17
PL428485A1 (pl) 2020-07-13
CN113272292B (zh) 2024-04-12
US20220073461A1 (en) 2022-03-10
WO2020145831A8 (en) 2021-07-15
WO2020145831A1 (en) 2020-07-16
CN113272292A (zh) 2021-08-17
AU2020207162A1 (en) 2021-07-15
JP2022522949A (ja) 2022-04-21
CA3125321A1 (en) 2020-07-16

Similar Documents

Publication Publication Date Title
GEP20237561B (en) Protein tyrosine phosphatase inhibitors
MX2023007192A (es) Inhibidores de prmt5.
PH12020551821A1 (en) Novel compounds
MX2022010011A (es) Inhibidores de prmt5 novedosos.
PH12021551256A1 (en) Pantetheine derivatives and uses thereof
MX2022004451A (es) Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.
MX2019012827A (es) Derivados de tetrahidronaftilo urea novedosos.
MX2021015854A (es) Composiciones y métodos para tratar trastornos del snc.
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
SA520411787B1 (ar) مشتقات بنزيميدازول واستخداماتها
MX2022004450A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1.
MX2019010096A (es) Derivados de 1, 4, 6-trisustituidos-2-alquil-1h-benzo[d]imidazol como inhibidores de dihidroorotato oxigenasa.
JOP20220227A1 (ar) مركبات بيرولو بيريميدين أمينات كمثبطات للمُتَمِّمِة
MX2023006504A (es) Compuesto de hidroxamato, metodo de preparacion del mismo y aplicacion del mismo.
MX2021010122A (es) Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos.
MX2021008213A (es) Derivados de (2,5-dioxopirrolidina-1-il)(fenil)-acetamida y su uso en el tratamiento de enfermedades neurologicas.
MX2022004197A (es) Inhibidores del factor d del complemento para administracion oral.
PH12019500618A1 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
MX2022013273A (es) Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus metodos de uso.
PH12019502652A1 (en) 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases
PH12020551341A1 (en) 4-methyldihydropyrimidinone compounds and pharmaceutical use thereof
MX2020011367A (es) Compuesto oxo-sustituido.
MX2022008487A (es) Degradadores de smarca2-vhl.
HK1149263A1 (en) Quinazoline-2,4-dione derivative, and medical compositions for the prophylaxis and treatment of cranial nerve disease containing the same
EA202190316A1 (ru) Конденсированное производное лактама